Deauville score and PET-adapted therapy
A 1-to-5 scale for how brightly a lymphoma lights up on a PET scan, compared with the liver and the middle of the chest. Scores of 1-3 after two cycles mean the treatment is working and allow it to be shortened; 4-5 means intensify.
The Deauville five-point scale (1 no uptake; 2 ≤ mediastinum; 3 ≤ liver; 4 moderately above liver; 5 markedly above or new lesions) underpins the Lugano response criteria for lymphoma. Interim PET after two cycles is used to omit bleomycin or radiotherapy in Hodgkin lymphoma (RATHL, HD16/HD17), to escalate to BEACOPP in non-responders, and to shorten R-CHOP in early-stage DLBCL (FLYER). PET-adapted de-escalation is spreading to HER2-positive breast cancer (PHERGain, omitting chemotherapy in PET responders). A complete metabolic response is the PET equivalent of complete remission.
Pages like this
not linked directly; found by shared links- TermLugano classification / Ann Arbor staging
Shares FDG PET, Hodgkin lymphoma, Diffuse large B-cell lymphoma.
- TermDeauville five-point scale
Shares FDG PET, Hodgkin lymphoma, Diffuse large B-cell lymphoma.
- TechnologyPET-adapted (response-adapted) therapy
Shares FDG PET, PET/CT, Hodgkin lymphoma, Diffuse large B-cell lymphoma.
- ProductVinblastine
Shares ABVD, BEACOPP and BrECADD (Hodgkin lymphoma regimens), Hodgkin lymphoma.
- ProductBleomycin
Shares ABVD, BEACOPP and BrECADD (Hodgkin lymphoma regimens), Hodgkin lymphoma.
- InstitutionUniversity Hospital Southampton / Centre for Cancer Immunology
Shares FDG PET, Hodgkin lymphoma, Diffuse large B-cell lymphoma.
- TermLate effects and survivorship toxicity
Shares ABVD, BEACOPP and BrECADD (Hodgkin lymphoma regimens), De-escalation, escalation and response-adapted therapy.
- TrialRATHL
Shares FDG PET, Hodgkin lymphoma.